publication venue for
- Navigating COPD and Bronchiectasis: A COPD Foundation Survey of Differences in Patient-Perceived Health Care Experiences by Sex.. 12:399-410. 2025
- Fall Risk and Medication Use Near End of Life Among Adults With Chronic Obstructive Pulmonary Disease.. 11:604-610. 2024
- Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression.. 11:196-205. 2024
- Disparities in Guideline Concordant Statin Treatment in Individuals With Chronic Obstructive Pulmonary Disease.. 10:369-379. 2023
- Changes in Lung Volumes with Spirometric Disease Progression in COPD.. 10:270-285. 2023
- Quality of Life and Mortality Outcomes for Augmentation Naïve and Augmented Patients with Severe Alpha-1 Antitrypsin Deficiency.. 10:139-147. 2023
- Patient-Reported Pulmonary Symptoms, Exacerbations, and Management in a Cohort of Patients With Alpha-1 Antitrypsin Deficiency.. 9:549-561. 2022
- Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument.. 9:195-208. 2022
- Exploring the Patient Experience with Noninvasive Ventilation: A Human-Centered Design Analysis to Inform Planning for Better Tolerance.. 9:80-94. 2022
- Pilot Study of a Patient Experience with an ELLIPTA Inhaler Electronic Medication Monitor and Associated Integrated System: A Prospective Observational Study Using the COPD Patient-Powered Research Network.. 8:488-501. 2021
- Self-reported COPD Medication Use and Adherence in the COPD Foundation Patient- Powered Registry Network.. 8:474-487. 2021
- Symptom Burden and Medication Use Among Patients with Nontuberculous Mycobacterial Lung Disease.. 8:243-254. 2021
- Home-Based Multicomponent Intervention Increases Exercise Activity and Improves Body Mass Index: Results of a 5-Year Randomized Trial Among Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease.. 8:7-18. 2021
- A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.. 7:346-361. 2020
- Nutrition and Markers of Disease Severity in Patients With Bronchiectasis.. 7:390-403. 2020
- The Burden of Cough and Phlegm in People With COPD: A COPD Patient-Powered Research Network Study.. 7:49-59. 2020
- Patient-Reported Consequences of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.. 6:132-144. 2019
- The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry.. 6:145-153. 2019
- Spirometry Measurement of Peak Inspiratory Flow Identifies Suboptimal Use of Dry Powder Inhalers in Ambulatory Patients with COPD.. 6:246-255. 2019
- Comparing Patients with ZZ Versus SZ Alpha-1 Antitrypsin Deficiency: Findings from AlphaNet's Disease Management Program.. 6:29-39. 2018
- National and State Estimates of COPD Morbidity and Mortality - United States, 2014-2015.. 5:324-333. 2018
- Lung, Fat and Bone: Increased Adiponectin Associates with the Combination of Smoking-Related Lung Disease and Osteoporosis.. 5:134-143. 2018
- Benefits Among Patients with Alpha-1 Antitrypsin Deficiency Enrolled in a Disease Management and Prevention Program.. 4:56-64. 2016
- Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans.. 1:105-114. 2014
- Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression. 2024
- Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression. 2024
- Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument. 2022